Genmab Reports 19% H1 2025 Revenue Growth, Completes Share Buyback Amid Strategic Advancements

Genmab AS reported a 19% increase in total revenue for H1 2025, driven by recurring revenue growth. Operating profit grew by 56%. The company completed a share buyback and ended the first half with $3 billion in cash. The EPCORE FL-1 study met its dual endpoints, supporting regulatory submissions. However, the company faces risks from delayed or unsuccessful development projects, regulatory approvals, and competitive pressure in the bispecific antibody market.

Genmab A/S (GMAB), a leading biotechnology company, reported robust financial results for the first half of 2025, highlighting significant growth across key metrics. The company's total revenue reached USD 1,640 million, marking a 19% increase compared to the same period in 2024 [1]. This growth was primarily driven by recurring revenue streams, including higher royalties from key collaborations and increased net product sales of EPKINLY [1].

Operating profit for the period grew by 56%, reaching USD 548 million. This impressive performance was bolstered by a 24% increase in royalty revenue, driven by stronger global net sales of DARZALEX by Johnson & Johnson and Kesimpta by Novartis [1]. Net financial income declined to USD 119 million from USD 204 million in the same period last year, mainly due to lower foreign exchange gains and reduced interest income [1].

The company also completed a share buyback, ending the first half with USD 3 billion in cash. Additionally, the EPCORE FL-1 study met its dual endpoints, supporting regulatory submissions [2]. Genmab's stock responded positively to the presentation, rising 5.35% to close at USD 21.51, with additional gains of 1.67% in premarket trading [3].

However, Genmab faces several risks, including delayed or unsuccessful development projects, regulatory approvals, and competitive pressure in the bispecific antibody market. The company's strategic partnerships with major pharmaceutical companies, such as AbbVie, Pfizer, Johnson & Johnson, Novartis, and Amgen, continue to drive its commercialized portfolio and royalty revenue streams [3].

Genmab is updating its revenue and operating profit guidance for 2025, with the improved outlook driven by higher total royalty revenues from DARZALEX. The revised guidance for 2025 is USD 3,500 to USD 3,700 in revenue, USD 2,945 to USD 3,090 in royalties, and USD 1,055 to USD 1,405 in operating profit [1].

References:

[1] https://ir.genmab.com/news-releases/news-release-details/genmab-announces-financial-results-first-half-2025
[2] https://www.nasdaq.com/articles/genmab-reports-strong-h1-2025-results-driven-higher-royalties-and-product-sales
[3] https://www.investing.com/news/company-news/genmab-h1-2025-slides-56-profit-growth-prompts-raised-guidance-93CH-4178126